.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Immuno-Oncology in Advanced Lung Cancer

EP. 1: NSCLC Immunotherapy: Transformation of Upfront Therapy

September 28th 2017

EP. 2: Upfront PD-L1 Blockade in Newly Diagnosed NSCLC

September 28th 2017

EP. 3: Patient Selection for Upfront Immunotherapy in NSCLC

September 28th 2017

EP. 4: Duration of Upfront Immunotherapy for NSCLC

September 28th 2017

EP. 5: The Potential for IO Use as Maintenance Therapy in NSCLC

September 28th 2017

EP. 6: Isolated Progression of NSCLC on Immunotherapy

September 28th 2017

EP. 7: Immunotherapy for Relapsed or Refractory NSCLC

September 28th 2017

EP. 8: The Role of Mutation Burden as a Biomarker in NSCLC

September 28th 2017

EP. 9: Combination Approaches for Second-Line Therapy for NSCLC

September 28th 2017

EP. 10: Treatment for NSCLC After Progression on Immunotherapy

September 28th 2017

EP. 11: Immunotherapy Toxicity Management in NSCLC

September 28th 2017

EP. 12: Immunotherapy for Management of Stage 3B NSCLC

September 28th 2017

EP. 13: PACIFIC Trial: Durvalumab for Stage 3 NSCLC

September 28th 2017

EP. 14: Promising Immunotherapy Agents for NSCLC

September 28th 2017

EP. 15: Immuno-Oncology Combination Therapy in NSCLC

September 28th 2017

EP. 16: Future Directions in NSCLC Immuno-Oncology Research

September 28th 2017